tradingkey.logo
搜尋

Neurosense Therapeutics Ltd

NRSN
添加自選
0.465USD
-0.011-2.27%
收盤 07-31 16:00美東報價延遲15分鐘
15.15M總市值
虧損本益比TTM

Neurosense Therapeutics Ltd

0.465
-0.011-2.27%

關於 Neurosense Therapeutics Ltd 公司

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Neurosense Therapeutics Ltd簡介

公司代碼NRSN
公司名稱Neurosense Therapeutics Ltd
上市日期Dec 09, 2021
CEOBen-Noon (Alon)
員工數量15
證券類型Ordinary Share
年結日Dec 09
公司地址11 Hamenofim St.
城市HERZLIYA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編4672562
電話97297996183
網址https://www.neurosense-tx.com/
公司代碼NRSN
上市日期Dec 09, 2021
CEOBen-Noon (Alon)

Neurosense Therapeutics Ltd公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--

常見問題

Neurosense Therapeutics Ltd的前五大股東是誰?

Neurosense Therapeutics Ltd的前五大股東如下:Mr. Alon Ben-Noon

有多少機構持有Neurosense Therapeutics Ltd(NRSN)的股份?

截至2026Q1,共有33家機構持有Neurosense Therapeutics Ltd的股份,合計持有的股份價值約為367.79K,占公司總股份的1.04% 。與2025Q4相比,機構持股有所增加,增幅為-2009158.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有